Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
A rare burst of visual creativity is seen occasionally in patients with frontotemporal dementia. A UCSF-led study offers new insights into how this talent develops as key areas of the brain degenerate.
The advent of cheap, easy-to-use blood tests for Alzheimer’s disease has the potential to revolutionize diagnosis and treatment. But they also raise difficult questions that the field is only beginning to consider.
UCSF researchers developed an approach to measure an over-the-counter allergy medication’s effectiveness in repairing brain damage from multiple sclerosis (MS), making it possible to also assess future therapies for the disorder.